Three-year Outcomes After Conversion From Monthly to Every 2-month Belatacept Maintenance Therapy in Kidney Transplant Recipients: Results From a Randomized Controlled Trial.

Autor:	Johnson AC; Emory Transplant Center, Atlanta, GA., Karadkhele GM; Emory Transplant Center, Atlanta, GA., Shenvi N; Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, GA., Easley KA; Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, GA., Larsen CP; Emory Transplant Center, Atlanta, GA., Badell IR; Emory Transplant Center, Atlanta, GA.
Jazyk:	angličtina
Zdroj:	Transplantation direct [Transplant Direct] 2023 Feb 08; Vol. 9 (3), pp. e1449. Date of Electronic Publication: 2023 Feb 08 (Print Publication: 2023).
DOI:	10.1097/TXD.0000000000001449
Abstrakt:	Maintenance immunosuppression with belatacept following kidney transplantation results in improved long-term graft function as compared with calcineurin inhibitors. However, broad application of belatacept has been limited, in part related to logistical barriers surrounding a monthly (q1m) infusion requirement. Methods: To determine whether every 2-mo (q2m) belatacept is noninferior to standard q1m maintenance, we conducted a prospective, single-center randomized trial in low-immunologic-risk, stable renal transplant recipients. Here, post hoc analysis of 3-y outcomes, including renal function and adverse events, are reported. Results: One hundred sixty-three patients received treatment in the q1m control group (n = 82) or q2m study group (n = 81). Renal allograft function as measured by baseline-adjusted estimated glomerular filtration rate was not significantly different between groups (time-averaged mean difference of 0.2 mL/min/1.73 m 2 ; 95% confidence interval: -2.5, 2.9). There were no statistically significant differences in time to death or graft loss, freedom from rejection, or freedom from donor-specific antibodies (DSAs). During the extended 12- to 36-mo follow-up, 3 deaths, 1 graft loss occurred in the q1m group, compared with 2 deaths, and 2 graft losses in the q2m group. In the q1m group, 1 patient developed DSAs and acute rejection. In the q2m group, 3 patients developed DSAs and 2 associated with acute rejection. Conclusions: Based on the similar renal function and survival at 36 mo compared with q1m, q2m belatacept is a potentially viable maintenance immunosuppressive strategy in low immunologic risk kidney transplant recipients that may facilitate increased clinical utilization of costimulation blockade-based immunosuppression. Competing Interests: The authors declare no conflicts of interest. (Copyright © 2023 The Author(s). Transplantation Direct. Published by Wolters Kluwer Health, Inc.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu